臨床研究等提出・公開システム

Efficacy of nicotinamide mononucleotide (NMN) for tinnitus

Efficacy of NMN for tinnitus

Takakura Hiromasa

Toyama University Hospital

2630 Sistani, Toyama, Toyama, Japan

hiromasa@med.u-toyama.ac.jp

Nakagawa Takashi

University of Toyama

2630 Sugitani, Toyama, Toyama, Japan

+81-76-434-7262

nakagawa@med.u-toyama.ac.jp

Recruiting

Jan. 27, 2023

Interventional

randomized controlled trial

double blind

placebo control

parallel assignment

treatment purpose

1) Outpatients aged 20 to 80 at the time of consent, regardless of gender
2) The first onset chronic, persistent, and subjective unilateral tinnitus whose duration is 2-18 months.
3) Unilateral or bilateral sensorineural hearing loss, with a hearing loss no less than 30 dB at 4,000 Hz or at 8,000 Hz
4) THI-12 total score no less than 9 and TRSw total score no less than 12
5) HADS depression score no more than 14 and HADS anxiety score no more than 14

a. Person with past or current malignant tumor
b. Person with severe comorbidities, such as heart, liver, kidney, blood, or mental diseases
c. Person with allergy against medicine or the test food
d. Pregnant, unwilling to practice contraception during the study, or lactating female
e. Person with middle ear disease
f. Person with a history of fluctuating hearing loss, ear fullness, or recurrent dizziness
g. Person with conductive hearing loss or mixed hearing loss
h. Person who have been treated for sudden deafness or acute sensorineural hearing loss within the past six months
i. Person who have taken prohibited drugs or treatments within 4 months prior to the start of the study, or person who have changed the dosage of drugs that are prohibited from being changed during the study period within 4 months prior to the start of the study
j. Person who is not judged as not qualified by the general administrator

Both

tinnitus

Oral administration of NMN 6 tablets/day (as NMN 250mg /day) or placebo 6 tablets/day for 12 weeks.

TRSw

TRSd, THI-12, HADS, Hearing test thresholds, safety (frequency of adverse events)

+81-76-415-8857

Jan. 11, 2023

No

none